Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder.

MLA

Karaaslan, Zerrin, et al. “Serum CXCL5 as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.” Northern Clinics of Istanbul, vol. 10, no. 3, May 2023, pp. 341–44. EBSCOhost, https://doi.org/10.14744/nci.2022.77861.

APA

Karaaslan, Z., Yilmaz, V., Yuceer, H., Sanli, E., Akcay, H. I., Kurtuncu, M., Turkoglu, R., & Tuzun, E. (2023). Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. Northern Clinics of Istanbul, 10(3), 341–344. https://doi.org/10.14744/nci.2022.77861

Chicago

Karaaslan, Zerrin, Vuslat Yilmaz, Hande Yuceer, Elif Sanli, Halil Ibrahim Akcay, Murat Kurtuncu, Recai Turkoglu, and Erdem Tuzun. 2023. “Serum CXCL5 as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.” Northern Clinics of Istanbul 10 (3): 341–44. doi:10.14744/nci.2022.77861.